Evaluating the safety of interferon therapy in compensated cirrhosis in chronic hepatitis B (IMAGE)

Chinese Medical Journals Publishing House Co., Ltd.

Evaluating the safety of interferon therapy in compensated cirrhosis in chronic hepatitis B

Caption

Researchers evaluated pegylated interferon-alpha (Peg-IFN-α) therapy in patients with Child-Pugh class A cirrhosis and found no higher risk of liver decompensation or severe adverse events compared to standard nucleos(t)ide analog treatment over 48 weeks.

Credit

Professor Wenhong Zhang from Huashan Hospital, Fudan University, and Professor Xiaolong Qi from Zhongda Hospital, Southeast University Image source link: https://onlinelibrary.wiley.com/doi/10.1002/poh2.70037

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted.

License

CC BY-NC

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.